YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Celgene to buy Impact for as much as $7B

Posted online

Celgene Corp. signed on to purchase blood-disease biotechnology company Impact Biomedicines.

The deal is worth as much as $7 billion, subject to milestones related to regulatory obstacles and sales performance.

Celgene agreed to make a $1.1 billion upfront payment for the San Diego-based privately held company.

Read more from The Wall Street Journal.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.

Nixa Superintendent Gearl Loden weighs in on A-F grade cards.

Most Read
Update cookies preferences